

Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with a FAB/LMB-based chemotherapy regimen with rituximab

Authors

Marie Emilie Dourthe,^{1,2} Anne Auperin,³ Charlotte Rigaud,⁴ Melissa Barbati,⁵ Jacinthe Bonneau,⁶ Nimrod Buchbinder,⁷ Marie-Laure Couec,⁸ Peggy Dartigues,⁹ Stéphane Ducassou,¹⁰ Nathalie Garnier,¹¹ Stéphanie Haouy,¹² Bénédicte Jonca,¹³ Anne Jourdain,¹⁴ Amaury Leruste,¹⁵ Thierry Molina,¹⁶ Françoise Montravers,¹³ Marlène Pasquet,¹⁷ Aurélie Phulpin,¹⁸ Maryline Poirée,¹⁹ Mathieu Simonin,²⁰ Alexandra Spiegel,²¹ Arnauld Verschuur,²² Thierry Leblanc,¹ Judith Landman-Parker,²⁰ Catherine Patte⁴ and Véronique Minard-Colin^{4,23}

¹Department of Pediatric Hematology and Immunology, Robert Debré University Hospital, AP-HP and University de Paris, Paris; ²Université Paris Cité, Institut Necker-Enfants Malades (INEM), Institut National de la Santé et de la Recherche Médicale (INSERM) U1151, Paris; ³Service de Biostatistique et d'Epidémiologie, Gustave Roussy Cancer Campus, INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif; ⁴Departments of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif; ⁵Department of Pediatric Oncology and Hematology, University Hospital of Lille, Lille; ⁶Department of Pediatric Oncology and Hematology, University Hospital of Rennes, Rennes; ⁷Department of Pediatric Oncology and Hematology, University Hospital of Rouen, Rouen; ⁸Pediatric Hematology and Oncology Department, University Hospital of Nantes, Nantes; ⁹Department of Biopathology, Morphology Unit, Gustave Roussy, Université Paris Saclay, Villejuif;

¹⁰Department of Pediatric Oncology and Hematology, University Hospital of Bordeaux, Bordeaux; ¹¹Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civils de Lyon, Lyon; ¹²Department of Pediatric Oncology and Hematology, University Hospital of Montpellier, Montpellier; ¹³Department of Nuclear Medicine, University Hospital Tenon, Paris; ¹⁴Department of Pediatric Oncology and Hematology, University Hospital of Tours, Tours; ¹⁵SIREDO Oncology Center, Institut Curie, PSL Research University, Paris; ¹⁶Department of Biopathology, University Hospital Necker Enfants Malades, Université Paris Cité, Paris; ¹⁷Department of Pediatric Oncology and Hematology, University Hospital of Toulouse, Toulouse; ¹⁸Pediatric Oncology and Hematology Department, University Hospital of Nancy (CHRU Nancy), Nancy; ¹⁹Department of Pediatric Oncology and Hematology, University Hospital of Nice, Nice; ²⁰Pediatric Hematology Oncology Department, Sorbonne Université/Trousseau Hospital, AP-HP, Paris; ²¹Pediatric Hematology Oncology Department, University Hospital of Strasbourg, Strasbourg; ²²Department of Pediatric Hematology Immunology and Oncology, La Timone Hospital, APHM, Marseille and ²³INSERM Unité 1015, Villejuif, France

Correspondence:

M.E. DOURTHE - marie-emilie.dourthe@aphp.fr

V. MINARD-COLIN - veronique.minard@gustaveroussy.fr

<https://doi.org/10.3324/haematol.2024.285403>

Supplementary results

Supplementary Table 1. Outline of the treatment for the 16 patients treated according to LMB 2001 protocol with rituximab

Nb patients	Prephase	Course 1	Course 2	Course 3	Course 4	Course 5	Course 6	Course 7	Course 8	Cumulative dose	
B	3	COP* Cy 300mg/m ² D1 VCR 2mg/m ² D1 IT (MTX HSHC) D1 pred 60mg/m ² /D D1-7	COPADM VCR 2mg/m ² D1 MTX 3g/m ² D1 Cy 250mg/m ² /12h D2-4 Adriamycin 60mg/m ² D2 IT (MTX HSHC) D2;6 pred 60mg/m ² D1-5	COPADM VCR 2mg/m ² D1 MTX 3g/m ² D1 Cy 250mg/m ² /12h D2-4 Adriamycin 60mg/m ² D2 IT (MTX HSHC) D2;6 pred 60mg/m ² D1-5	CYM MTX 3g/m ² D1 cytarabine 100mg/m ² /D D2-6 IVC 24h IT (MTX HSHC D2; HSHC araC D7)	CYM MTX 3g/m ² D1 cytarabine 100mg/m ² /D D2- 6 IVC 24h IT (MTX HSHC D2; HSHC araC D7)				Cyclophosphamide= 3300mg/m² Adriamycin= 120mg/m² IT=8*	
C1	13	COP* Cy 300mg/m ² D1 VCR 2mg/m ² D1 IT (MTX HSHC araC) D1, D3, D5 pred 60mg/m ² /D D1-7	COPADM VCR 2mg/m ² D1 MTX 8g/m ² D1 Cy 250mg/m ² /12h D2-4 Adriamycin 60mg/m ² D2 IT (MTX HSHC AraC) D2, 4, 6 pred 60mg/m ² D1-5	COPADM VCR 2mg/m ² D1 MTX 8g/m ² D1 Cy 500mg/m ² /12h D2-4 Adriamycin 60mg/m ² D2 IT (MTX HSHC AraC) D2, 4, 6 pred 60mg/m ² D1-5	CYVE cytarabine 50mg/m ² IVC 12h D1-5 Cytarabine 3g/m ² D2-5 VP16 200mg/m ² D2-5	CYVE cytarabine 50mg/m ² IVC 12h D1-5 Cytarabine 3g/m ² D2-5 VP16 200mg/m ² D2-5	Seq1 VCR 2mg/m ² D1 MTX 8g/m ² D1 Cy 500mg/m ² /d D2-3 Adriamycin 60mg/m ² D2 IT (MTX HSHC AraC) D2 pred 60mg/m ² D1-5	Seq2 Cytarabine 50mg/m ² /12h D1-5 VP16 150mg/m ² D1-3	Seq3 VCR 2mg/m ² D1 Cy 500mg/m ² /d D1-2 Adriamycin 60mg/m ² D1 pred 60mg/m ² D1-5	Seq4 Cytarabine 50mg/m ² /1 2h D1-5 VP16 150 mg/m ² D1- 3	Cyclophosphamide= 6800mg/m² Adriamycin= 240mg/m² IT=7*
R		375mg/m ² D1	375mg/m ² D1	375mg/m ² D1	375mg/m ² D1	375mg/m ² D1	375mg/m ² D1				

Abbreviations: Adriamycin, doxorubicin; AraC, aracytine; VCR, vincristine; MTX, methotrexate; Cy, cyclophosphamide; pred, prednisolone; IT: intrathecal; R, Rituximab; RA, remission assessment

*A COP prephase is not mandatory but may be required one week prior to commencement of course 1 for patients requiring urgent treatment whilst awaiting histological confirmation. In case of COP prephase more intrathecal are administered. #remission assessment was required after 4 or 6 courses of chemotherapy. At the end of therapy, if PET-CT is positive, or a large residual tumor remains, then biopsy/removal of the residual mass is recommended. No treatment decisions were to be based on PET-CT results only.


Supplementary Table 2. Events characteristics

Patient	#2	#23	#43
Site of progression /relapse	mediastin	mediastin	mediastin*
Time from diagnosis	Viable cells in residual mass after RCYVE2 6.2 months	Progression after RCOPADM1 0.6 months	Relapse at 6.6 months
2nd line chemotherapy	R-ICE (2) Bv-Nivo (4)	R-ICE (3)	R-ICE (2) Ibrutinib (3)
High dose chemotherapy	BEAM and ASCT	BEAM and ASCT	BEAM and ASCT
Radiation therapy	yes	yes	yes
Patient status at last news	CR1 1.9 year	CR1 11 years	CR2 5.6 years

Abbreviations: ASCT, autologous stem cell transplantation; BEAM, Carmustine, etoposide, cytarabine, melphalan; Bv, Brentuximab-Vedotin; CR, complete response; ICE, ifosfamide, etoposide, carboplatin; Nivo, nivolumab ; R, Rituximab.

*Residual mass after 6 courses, necrosis at histological analysis. Relapse as « Burkitt like »/DLBCL

Supplementary Figure 1. 18F-FDG-PET results and outcome



Abbreviations: pts, patients; EOT: end of treatment; DS, Deauville score

*Deauville score =5